Metallo-beta-lactamase (MBL)-producing bacteria are an important concern in modern healthcare because they can resist several widely used beta-lactam antibiotics. These bacteria produce enzymes that break down certain antibiotics, making some infections more difficult to treat.
Understanding MBL-producing bacteria, their resistance mechanisms, and the role of newer antibiotic combinations is essential for microbiology research, pharmaceutical science, and antimicrobial stewardship.
In particular, the combination of aztreonam and avibactam has attracted attention because its two components have complementary roles against selected bacterial resistance mechanisms.
What Are MBL-Producing Bacteria?
Metallo-beta-lactamases are enzymes belonging to Ambler class B beta-lactamases. They use zinc ions at their active site to hydrolyze many beta-lactam antibiotics, including carbapenems.
MBL-producing bacteria may belong to different Gram-negative bacterial species, including Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.
The presence of an MBL can significantly affect antibiotic susceptibility. The overall resistance profile also depends on whether the bacterium produces other beta-lactamases or possesses additional resistance mechanisms.
For a broader understanding of how antibiotic resistance develops, see our related article on the mechanism of action of avibactam.
Common Types of Metallo-Beta-Lactamases
Several MBL families are clinically important because of their ability to inactivate multiple beta-lactam antibiotics.
1. New Delhi Metallo-Beta-Lactamase (NDM)
NDM enzymes are associated with resistance to carbapenems and several other beta-lactam antibiotics.
NDM-producing bacteria have been identified in various Gram-negative species. The genes encoding these enzymes can occur on mobile genetic elements, which may facilitate the spread of resistance between bacteria.
2. Verona Integron-Encoded Metallo-Beta-Lactamase (VIM)
VIM enzymes are another important family of metallo-beta-lactamases. They have been detected in several Gram-negative organisms, including Pseudomonas aeruginosa and members of the Enterobacterales group.
Their presence can limit the effectiveness of multiple beta-lactam antibiotics.
3. Imipenemase Metallo-Beta-Lactamase (IMP)
IMP enzymes can also contribute to carbapenem resistance. Their distribution varies across bacterial populations and geographic regions.
Identifying the specific resistance mechanism can help laboratories and healthcare professionals interpret susceptibility results more effectively.
How Do MBL Enzymes Cause Antibiotic Resistance?
Beta-lactam antibiotics act by interfering with bacterial cell-wall synthesis. They bind to susceptible penicillin-binding proteins and disrupt the processes required to maintain the cell wall.
MBL enzymes hydrolyze the beta-lactam ring of susceptible antibiotics, reducing or eliminating their antibacterial activity.
However, MBLs do not inactivate every antibiotic. For example, aztreonam is generally stable against hydrolysis by MBL enzymes, although other beta-lactamases produced by the same bacterium may compromise its activity.
This distinction is important when evaluating antibiotic combinations designed to address specific resistance mechanisms.
Why Are MBL-Producing Bacteria Difficult to Treat?
Treatment decisions involving MBL-producing bacteria can be complicated by several factors.
Multiple resistance mechanisms: A bacterium may produce an MBL alongside extended-spectrum beta-lactamases (ESBLs), AmpC enzymes, or other resistance determinants.
Reduced antibiotic activity: MBLs can compromise the activity of several beta-lactam antibiotics, including carbapenems.
Additional bacterial defenses: Changes in membrane permeability, antibiotic targets, and efflux systems may contribute to resistance.
Variable susceptibility: Bacteria from the same species can have different resistance profiles, making laboratory susceptibility testing important.
For these reasons, identifying resistance mechanisms is an important part of evaluating treatment options for difficult-to-treat bacterial infections.
Aztreonam-Avibactam and MBL-Producing Bacteria
Aztreonam-avibactam combines an antibiotic with a beta-lactamase inhibitor. Its mechanism is based on the complementary properties of the two components.
Role of Aztreonam
Aztreonam is a monobactam antibiotic that interferes with bacterial cell-wall synthesis. It is generally stable against hydrolysis by metallo-beta-lactamases.
Nevertheless, other enzymes produced by the same bacterium may degrade aztreonam and reduce its activity.
Role of Avibactam
Avibactam is a non-beta-lactam beta-lactamase inhibitor. It inhibits many class A and class C beta-lactamases and certain class D enzymes.
Importantly, avibactam does not directly inhibit MBL enzymes. Instead, it can inhibit certain additional beta-lactamases that might otherwise compromise aztreonam.
Why the Combination Matters
The combination is designed to address selected resistance mechanisms by allowing aztreonam to act against susceptible bacteria while avibactam inhibits certain accompanying beta-lactamases.
Its activity depends on the bacterial species, the complete resistance profile, susceptibility results, and the relevant clinical context.
For a more detailed explanation, read our related article on aztreonam-avibactam: mechanism of action and antibiotic resistance.
MBL Resistance and Pharmaceutical Research
Research into antibiotic resistance continues to influence pharmaceutical development, diagnostic testing, and antimicrobial stewardship.
Scientists study bacterial enzymes, resistance genes, and antibiotic interactions to better understand why some treatments remain effective against particular organisms while others do not.
Antimicrobial susceptibility testing and molecular diagnostics can provide complementary information. Molecular tests may identify resistance genes, while susceptibility tests help evaluate how a particular bacterial isolate responds to selected antibiotics.
Neither approach should be interpreted without considering the organism, the clinical context, and applicable guidelines.
Meblanios: Aztreonam and Avibactam Injection
For readers interested in the corresponding pharmaceutical product, AIONIOS Pharma provides a dedicated page for Meblanios — Aztreonam and Avibactam Injection.
The product page provides information about Meblanios and its stated composition. Consult verified product documentation for the exact formulation, approved indications, contraindications, safety information, and administration requirements.
Product information is not a substitute for professional medical advice or prescribing guidance.
Frequently Asked Questions
What are MBL-producing bacteria?
MBL-producing bacteria produce metallo-beta-lactamase enzymes that can inactivate many beta-lactam antibiotics, including carbapenems.
What are the major types of MBL enzymes?
Important families include NDM, VIM, and IMP. Each can contribute to antibiotic resistance in different Gram-negative bacterial species.
Does avibactam inhibit MBL enzymes directly?
No. Avibactam does not directly inhibit metallo-beta-lactamases. In the aztreonam-avibactam combination, avibactam inhibits certain other beta-lactamases that could otherwise degrade aztreonam.
Why is aztreonam relevant to MBL resistance?
Aztreonam is generally stable against hydrolysis by MBLs. However, other beta-lactamases may compromise its activity, which explains the scientific rationale for combining it with avibactam.
Where can I find Meblanios product information?
Visit the Meblanios product page on the AIONIOS Pharma website for available product information.
Conclusion
MBL-producing bacteria represent an important challenge in antimicrobial resistance because they can inactivate several widely used beta-lactam antibiotics.
Understanding NDM, VIM, and IMP enzymes, as well as the additional resistance mechanisms that bacteria may possess, helps explain why treatment selection can be complex.
Aztreonam-avibactam illustrates an approach that combines an antibiotic with an inhibitor of selected beta-lactamases. Appropriate use depends on susceptibility results, accurate clinical assessment, and verified prescribing information.
Continued research, effective diagnostics, and responsible antibiotic use remain essential for addressing antimicrobial resistance.